Imaging Procedure Using ALA in Finding Residual Tumor in Grade IV Malignant Astrocytoma

Model scores of the 29,894 trials active now.

Model score 25% for any early termination, 14% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2018-10-14. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: tumorbrainradiationimagingtumors
  Phrases that lowered it: participantsadultparticipantindividualsdiagnosed
• Drug's FAERS reports with a death: 80% (raises risk) · Drug's FDA history
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Number of arms: 4 (lowers risk) · Design
• Primary purpose: diagnostic (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Responsible party: sponsor investigator (raises risk) · Design
• Design: parallel (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Disease area, neurology: Yes (raises risk) · Disease area
• Blinding: single (lowers risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 100% (raises risk) · Drug's FDA history
• Sponsor's past trials: 0 (raises risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study of Aminolevulinic Acid to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain NCT00671710 · started 2008 · scored riskier than 98% of active trials completed
• Safety Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Tumors of the Brain NCT01116661 · started 2010 · scored riskier than 99% of active trials terminated
• A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors NCT01351519 · started 2011 · scored riskier than 99% of active trials terminated
• A Study of the Specificity and Sensitivity of 5- Aminolevulinic Acid (ALA) Fluorescence in Malignant Brain Tumors NCT01128218 · started 2011 · scored riskier than 97% of active trials completed
• Safety Study of Aminolevulinic Acid (ALA) to Improve Visibility of Brain Tumors During Surgery NCT00961090 · started 2009 · scored riskier than 99% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.